Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of IDP-123 Lotion vs Tazorac Cream in Acne
NCT02849873Phase 1Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Jun 2016
- Primary completion
- Dec 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tazarotene in acne vulgaris (2 arms), sponsored by Valeant Pharmaceuticals. Primary endpoints: Evaluator's Global Severity Score at Day 15 and Pharmacokinetic Parameters at Day 15. Started Jun 2016; status: completed.
02
Drugs
tazarotene
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT02849873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02849873.